Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States.

Urologic oncology·2026
Same author

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

Future oncology (London, England)·2026
Same author

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.

International journal of clinical oncology·2026
Same author

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate cancer and prostatic diseases·2026
Same author

Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States.

ClinicoEconomics and outcomes research : CEOR·2026

Related Experiment Video

Updated: Jan 13, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K

Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T.

Neal D Shore1, Emmanuel S Antonarakis2, Jason Hafron3

  • 1Genitourinary Oncology Center of Excellence, START Carolinas/Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA.

Prostate Cancer
|January 7, 2026
PubMed
Summary

Sipuleucel-T, a cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC), offers a unique mechanism targeting PAP-expressing cells. Real-world data confirm its survival benefit and highlight patient factors influencing outcomes in mCRPC.

Keywords:
immunotherapyprostate cancersipuleucel-T

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Related Experiment Videos

Last Updated: Jan 13, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Area of Science:

  • Oncology
  • Immunotherapy
  • Prostate Cancer Research

Background:

  • Sipuleucel-T, the first cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC), was approved 15 years ago.
  • The treatment landscape for advanced prostate cancer has significantly evolved since its approval.
  • Sipuleucel-T is a personalized immunotherapy activating the patient's immune system against prostatic acid phosphatase (PAP)-expressing tumor cells.

Purpose of the Study:

  • To review the clinical benefit and immune responses of sipuleucel-T in mCRPC patients.
  • To identify patient-specific factors associated with improved survival.
  • To emphasize the unique mechanism of sipuleucel-T within current mCRPC treatment paradigms.

Main Methods:

  • Review of clinical trials and real-world data for sipuleucel-T in mCRPC.
  • Analysis of immune and biologic responses induced by sipuleucel-T.
  • Identification of prognostic factors for survival in patients treated with sipuleucel-T.

Main Results:

  • Sipuleucel-T demonstrates a survival benefit in patients with nonopioid-requiring mCRPC.
  • Extensive data confirm sipuleucel-T's clinical efficacy and its induction of immune responses.
  • Patient race, baseline disease burden, and treatment-induced immune responses are associated with longer survival.

Conclusions:

  • Sipuleucel-T remains a unique therapeutic option for mCRPC due to its distinct mechanism of action.
  • Maximizing the appropriate clinical utilization of sipuleucel-T in mCRPC is essential.
  • Further understanding of sipuleucel-T's role in combination therapies may enhance its utility.